Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASSIFY: Clarithromycin to Prevent Secondary Infections in Sepsis
NCT07834346Phase 3Recruiting
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 3 trial of clarithromycin in sepsis, community acquired pneumonia (CAP), sponsored by Hellenic Institute for the Study of Sepsis. Started Sep 2026; status: recruiting.
02
Drugs
clarithromycin
03
Conditions
sepsiscommunity acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT07834346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07834346.